$AZYO News

Last published 3y ago

3y agoAZYO ELUTElutia to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireSILVER SPRING, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive
3y agoAZYOAziyo Biologics Rebrands as Elutia to Reflect Strategic Focus on Drug Eluting BiomatricesGlobeNewswire– Company to begin trading under new ticker symbol "ELUT" – SILVER SPRING, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo") today announced a change of the Company's name to Elutia
3y agoAZYOAziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative ProceduresGlobeNewswireCase provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket SILVER SPRING, Md., Aug. 30, 2023
3y agoAZYOAziyo Biologics, Inc. (AZYO) Q2 2023 Earnings Call TranscriptEarnings Call Transcripts
3y agoAZYOAziyo Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues to Drug-Eluting Biomatrix CompanyGlobeNewswireNegotiating multiple LOIs to divest Orthopedic business CanGaroo® RM 510(k) resubmission to the FDA remains on track SimpliDerm® quarterly net sales up 32% year-over-year Successful transfer of
3y agoAZYOAziyo Biologics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023GlobeNewswireSILVER SPRING, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the
3y agoAZYO BIOL BTCY ETON+2SWK Holdings Highlights Recent Achievements and Provides Portfolio UpdatePR NewswireDALLAS, July 17, 2023 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage
3y agoAZYOAziyo Biologics Announces Voluntary Recall of Viable Bone Matrix ProductsGlobeNewswireSILVER SPRING, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients
3y agoAZYOAziyo Biologics Presents Positive Clinical Data on CanGaroo® Biologic EnvelopeGlobeNewswireStudy Presented at Heart Rhythm Society Supports Wound-Healing Benefits in Patients Receiving Cardiac Implantable Electronic Devices SILVER SPRING, Md., May 19, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc.
3y agoAZYOAziyo Biologics Reports Highest Sales and Gross Profit in Company HistoryGlobeNewswire- All Four Business Segments Achieved Growth Led by Strong SimpliDerm and CanGaroo Sales - SILVER SPRING, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops
3y agoAZYOAziyo Biologics to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023GlobeNewswireSILVER SPRING, Md., May 03, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and the
3y agoAZYO LMATAziyo Biologics and LeMaitre Vascular Partner for the Distribution of Aziyo's Cardiovascular PortfolioGlobeNewswireSILVER SPRING, Md., April 20, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and
3y agoAZYO LMATLeMaitre to Distribute Aziyo Biologics' Cardiovascular PatchesGlobeNewswireBURLINGTON, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants and services, announced today it has entered into an agreement with Aziyo Biologics,
3y agoAZYOAziyo Biologics Reports Record Full Year 2022 RevenuesGlobeNewswireSILVER SPRING, Md., March 22, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and
3y agoAZYO SIENAziyo Biologics and Sientra Announce SimpliDerm® Partnership to Improve Women's Access to Biologics for Soft Tissue ReconstructionGlobeNewswireSILVER SPRING, Md. and IRVINE, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between
3y agoAZYOAziyo Biologics Provides Update on FDA Submission for CanGaroo® RM Antibacterial EnvelopeGlobeNewswireSILVER SPRING, Md., March 20, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients
3y agoAZYOAziyo Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 22, 2023GlobeNewswireSILVER SPRING, Md., March 15, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a company that develops and commercializes biologic products to improve compatibility between medical devices and
3y agoACER AZYO BIOL ETON+1SWK Holdings Provides Portfolio Update Highlighting Recent AchievementsPR NewswireFourth Quarter and Full Year 2022 Financial Results to be Announced in March DALLAS, Jan. 31, 2023 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused
3y agoAZYOAziyo Biologics Announces Record Annual Net Sales in Preliminary (Unaudited) Fourth Quarter and Full Year 2022 Topline ResultsGlobeNewswireSILVER SPRING, Md., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical
3y agoAZYOAziyo Biologics Announces Funding of Additional $4 Million Term Loan with SWK Holdings CorporationGlobeNewswireFollows recent equity financing, resulting in debt and equity gross proceeds of $15.2 million SILVER SPRING, Md., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a biologics company
3y agoAZYOAziyo Biologics, Inc. Announces Pricing of $11.2 Million Public Offering of Common StockGlobeNewswireSILVER SPRING, Md., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical
3y agoAZYOAziyo Biologics, Inc. Announces Proposed Public Offering of Common StockGlobeNewswireSILVER SPRING, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) ("Aziyo"), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical
3y agoAZYOAziyo Biologics to Participate in Upcoming Investor ConferencesGlobeNewswireSILVER SPRING, Md., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the
3y agoAZYOAziyo Biologics Reports Strong Third Quarter 2022 RevenueGlobeNewswirePositive meeting with FDA provides clarity for CanGaroo® RM clearance SILVER SPRING, Md., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a biologics company with a portfolio of
4y agoAZYO SWKHSWK Holdings Corporation Announces Financial Results for Third Quarter 2022PR NewswireConference Call and Live Audio Webcast Scheduled for Thursday, November 10, 2022, at 10:00 a.m. ET Corporate Highlights Successful leadership transition with Jody Staggs named President and Interim Chief Executive
4y agoAZYOAziyo Biologics to Report Third Quarter 2022 Financial Results on November 14, 2022GlobeNewswireSILVER SPRING, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a regenerative medicine company with a portfolio of commercial therapies, today announced that it will release third quarter
4y agoAZYOAziyo Biologics Appoints Seasoned Healthcare Executive, David Colpman, to Board of DirectorsGlobeNewswireSILVER SPRING, Md., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a regenerative medicine company with a portfolio of commercial therapies, today announced the appointment of David Colpman to
4y agoACER AZYO BIOL BTCY+2SWK Holdings Provides Portfolio Update Highlighting Recent AchievementsPR NewswireThird Quarter 2022 Financial Results to be Announced in Early November DALLAS, Oct. 18, 2022 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science focused
4y agoAZYOAziyo Biologics Strengthens Leadership Team and Organizes for Growth in Key MarketsGlobeNewswireSILVER SPRING, Md., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a biological device company with a portfolio of commercial products across four distinct businesses, today announced key
4y agoAZYOAziyo Biologics Appoints Michelle LeRoux Williams, Ph.D as Chief Scientific OfficerGlobeNewswireSILVER SPRING, Md., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company announced today that Michelle LeRoux Williams, Ph.D. has been appointed Chief Scientific Officer. "Aziyo stri
4y agoAZYOAziyo Biologics to Present at the Inaugural Gilmartin Group Emerging Growth Company ShowcaseGlobeNewswireSILVER SPRING, Md., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company, today announced the company will present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Show
4y agoAZYOAziyo Biologics Announces Second Quarter 2022 Financial Results and Recent Business Achievements, Including Robust Revenue Growth and Strengthened Balance SheetGlobeNewswireSILVER SPRING, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company, today provided a business update and reported financial results for the second quarter June 30, 2022. Recent
4y agoAZYOAziyo Biologics Announces $25 Million Loan Facility with SWK HoldingsGlobeNewswireSILVER SPRING, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO) (the "Company"), a commercial-stage regenerative medicine company announced today that it has entered into a $25 million credit facility from SWK Holdings Corpora
4y agoAZYOAziyo Biologics Co-Founder and Regenerative Medicine Pioneer, Dr. Randy Mills, appointed Chief Executive OfficerGlobeNewswireSILVER SPRING, Md., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company, today announced that Aziyo co-founder C. Randal (Randy) Mills, Ph.D. has assumed the President and Chief Execut
4y agoAZYOAziyo Biologics to Report Second Quarter 2022 Financial Results on August 11, 2022GlobeNewswireSILVER SPRING, Md., July 28, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing
4y agoAZYOAziyo Biologics Appoints Dr. C. Randal Mills as Interim President and CEOGlobeNewswireSILVER SPRING, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing
4y agoAZYOAziyo Biologics Provides Business Update and Reports First Quarter 2022 Financial ResultsGlobeNewswireSILVER SPRING, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing
4y agoAZYOAziyo Biologics to Report First Quarter 2022 Financial Results on Monday, May 9, 2022GlobeNewswireSILVER SPRING, Md., April 25, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoin
4y agoAZYOAziyo Biologics Announces Upcoming KOL Call Hosted by CowenGlobeNewswireSILVER SPRING, Md., April 12, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoin
4y agoAZYOAziyo Announces FDA 510(k) Submission for CanGaroo® RM, its Next-Generation Biomaterial Envelope Enhanced with AntibioticsGlobeNewswireSILVER SPRING, Md., April 04, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), today announced the Company has filed a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for CanGaroo® RM Antibacterial Envelope, i
4y agoAZYOAziyo Biologics to Participate in the Lytham Partners Spring 2022 Investor ConferenceGlobeNewswireSILVER SPRING, Md., March 31, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoin
4y agoAZYOAziyo Biologics Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewswireSILVER SPRING, Md., March 03, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoin
4y agoAZYOAziyo Biologics to Participate in the Cowen 42nd Annual Health Care ConferenceGlobeNewswireSILVER SPRING, Md., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing
4y agoAZYOAziyo Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 3, 2022GlobeNewswireSILVER SPRING, Md., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing
4y agoAZYOAziyo Biologics to Present at the H.C. Wainwright Bioconnect Virtual ConferenceGlobeNewswireSILVER SPRING, Md., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing
4y agoAZYOAziyo Biologics Announces Closing of $14.0 Million Private PlacementGlobeNewswireSILVER SPRING, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (the "Company"), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoi
4y agoAZYOAziyo Biologics Announces $14.0 Million Private PlacementGlobeNewswireSILVER SPRING, Md., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (the "Company") today announced that it has entered into a definitive agreement to sell securities in a private placement that is expected to result in gross proceeds to the Co
4y agoAZYOAziyo Biologics to Participate in Upcoming Virtual Investor ConferencesGlobeNewswireSILVER SPRING, Md., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing
5y agoAZYOAziyo Biologics Reports Third Quarter 2021 Financial ResultsGlobeNewswireSILVER SPRING, Md., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing
5y agoAZYOAziyo Biologics Provides Business Update and Preliminary Third Quarter 2021 Revenue Results and Announces Timing for Third Quarter 2021 Financial ResultsGlobeNewswireSILVER SPRING, Md., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing